Simple Summary As life expectancy is increasing, the older population is rapidly growing.
However, older patients with cancer are still underrepresented in clinical trials, making …

The tumor microenvironment (TME) is a major contributor to cancer malignancy including
development of therapeutic resistance, a process mediated in part through intercellular …

Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer with a
poor prognosis and limited effective therapeutic options. Induction of senescence, arrest of …

Over the past few decades, cellular senescence has been identified in cancer patients
undergoing chemotherapy and radiotherapy. Senescent cells are generally characterized by …

Since therapy‐induced senescence (TIS) can either support or inhibit cancer progression,
identifying which types of chemotherapeutic agents can produce the strongest anti‐tumor …

Cancer progression is supported by the cross-talk between tumor cells and the surrounding
stroma. In this context, senescent cells in the tumor microenvironment contribute to the …

Triple negative breast cancer (TNBC) is classically treated with combination
chemotherapies. Although, initially responsive to chemotherapies, TNBC patients frequently …

More than 75% of epithelial ovarian cancer (EOC) patients experience disease recurrence
after initial treatment, highlighting our incomplete understanding of how chemoresistant …

Cellular senescence process results in stable cell cycle arrest, which prevents cell
proliferation. It can be induced by a variety of stimuli including metabolic stress, DNA …

Ageing is a complex biological phenomenon representing the major risk factor for
developing age-related diseases, such as cardiovascular pathologies, neurodegenerative …